(Q33993706)

30 July 2017

1 reference

title

Eprosartan: a review of its use in the management of hypertension. (English)

1 reference

30 July 2017

Plosker GL

1

1 reference

30 July 2017

Foster RH

series ordinal

2

1 reference

30 July 2017

publication date

1 July 2000

1 reference

30 July 2017

1 reference

30 July 2017

volume

60

1 reference

30 July 2017

issue

1

1 reference

30 July 2017

page(s)

177-201

1 reference

Pharmacology of eprosartan, an angiotensin II receptor antagonist: exploring hypotheses from clinical data

30 July 2017

cites work

1 reference

12 December 2020

Characterization of renal angiotensin II receptors using subtype selective antagonists

1 reference

12 December 2020

Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology

1 reference

12 December 2020

Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators

1 reference

12 December 2020

The efficacy and tolerance of one or two daily doses of eprosartan in essential hypertension. The Eprosartan Multinational Study Group

1 reference

12 December 2020

Eprosartan, an angiotensin II receptor antagonist, does not affect the pharmacodynamics of glyburide in patients with type II diabetes mellitus

1 reference

12 December 2020

Cough and ACE inhibitors

1 reference

12 December 2020

Effect of hepatic disease on the pharmacokinetics and plasma protein binding of eprosartan

1 reference

12 December 2020

Effect of captopril and the nonpeptide angiotensin II antagonists, SK&F 108566 and EXP3174, on renal function in dogs with a renal artery stenosis

1 reference

12 December 2020

Pharmacokinetics of eprosartan in healthy subjects, patients with hypertension, and special populations

1 reference

12 December 2020

Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group

1 reference

12 December 2020

Effects of Eprosartan Versus Enalapril in Hypertensive Patients on the Renin-Angiotensin-Aldosterone System and Safety Parameters: Results from a 26-Week, Double-blind, Multicentre Study

1 reference

12 December 2020

Angiotensin II receptor subtypes: selective antagonists and functional correlates

1 reference

12 December 2020

Guidelines for management of hypertension: report of the third working party of the British Hypertension Society

1 reference

12 December 2020

Angiotensin II receptor antagonists

1 reference

12 December 2020

The effects of eprosartan, an angiotensin II AT1 receptor antagonist, on uric acid excretion in patients with mild to moderate essential hypertension

1 reference

12 December 2020

Practical considerations of the pharmacology of angiotensin receptor blockers

1 reference

12 December 2020

Angiotensin converting enzyme inhibitors and cough

1 reference

12 December 2020

Effect of ranitidine on the pharmacokinetics of orally administered eprosartan, an angiotensin II antagonist, in healthy male volunteers.

1 reference

12 December 2020

Renin-angiotensin system: biochemistry and mechanisms of action

1 reference

12 December 2020

1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee

1 reference

12 December 2020

A dose proportionality study of eprosartan in healthy male volunteers

1 reference

12 December 2020

Pharmacokinetics and protein binding of eprosartan in hemodialysis-dependent patients with end-stage renal disease.

1 reference

12 December 2020

Angiotensin II receptor subtypes in the kidney

1 reference

12 December 2020

Pharmacokinetics and protein binding of eprosartan in healthy volunteers and in patients with varying degrees of renal impairment.

1 reference

12 December 2020

The renal profile of eprosartan

1 reference

12 December 2020

Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers

1 reference

12 December 2020

Effect of age and gender on the pharmacokinetics of eprosartan

1 reference

12 December 2020

Lack of effect of eprosartan on the single dose pharmacokinetics of orally administered digoxin in healthy male volunteers

1 reference

12 December 2020

A review of eprosartan pharmacokinetic and pharmacodynamic drug interaction studies

1 reference

12 December 2020

The diastolic blood pressure in systolic hypertension

1 reference

12 December 2020

Renal hemodynamic response to an angiotensin II antagonist, eprosartan, in healthy men

1 reference

12 December 2020

The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure

1 reference

12 December 2020

British Hypertension Society guidelines for hypertension management 1999: summary

1 reference

12 December 2020

Angiotensin II receptors and angiotensin II receptor antagonists.

1 reference

12 December 2020

Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study.

1 reference

12 December 2020

Double-blind comparison of eprosartan and enalapril on cough and blood pressure in unselected hypertensive patients. Eprosartan Study Group.

1 reference

12 December 2020

Antihypertensive activity of the non-peptide angiotensin II receptor antagonist, SK&F 108566, in rats and dogs

1 reference

12 December 2020

Effect of long-term eprosartan versus enalapril antihypertensive therapy on left ventricular mass and coronary flow reserve in stage I-II hypertension. Eprosartan Study Group

1 reference

12 December 2020

Eprosartan does not affect the pharmacodynamics of warfarin

1 reference

12 December 2020

Inhibition of sympathetic outflow by the angiotensin II receptor antagonist, eprosartan, but not by losartan, valsartan or irbesartan: relationship to differences in prejunctional angiotensin II receptor blockade

1 reference

12 December 2020

Putative mechanisms of cough after treatment with angiotensin converting enzyme inhibitors

1 reference

12 December 2020

Safety and tolerability of eprosartan

1 reference

12 December 2020

Angiotensin II inhibits glomerular adenylate cyclase via the angiotensin II receptor subtype 1 (AT1)

1 reference

12 December 2020

Chinese Trial on Isolated Systolic Hypertension in the Elderly

1 reference

12 December 2020

A dose-response study to assess the renal hemodynamic, vascular, and hormonal effects of eprosartan, an angiotensin II AT1-receptor antagonist, in sodium-replete healthy men

1 reference

12 December 2020

Pharmacological characterization of the nonpeptide angiotensin II receptor antagonist, SK&F 108566

1 reference

12 December 2020

Persistent dry cough with enalapril: incidence depends on method used

1 reference

12 December 2020

Interaction of nonpeptide angiotensin II receptor antagonists with the urate transporter in rat renal brush-border membranes

1 reference

12 December 2020

Renin-angiotensin system inhibition reduces glycine-induced glomerular hyperfiltration in conscious rats

1 reference

12 December 2020

Effect of eprosartan and losartan on uric acid metabolism in patients with essential hypertension

1 reference

12 December 2020

Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects

1 reference

12 December 2020

Comparative antihypertensive effects of angiotensin II receptor antagonists

1 reference

12 December 2020

Efficacy and safety of eprosartan in severe hypertension. Eprosartan Multinational Study Group

1 reference

12 December 2020

Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension

1 reference

12 December 2020

Angiotensin-converting enzyme inhibitors in hypertension. A dozen years of experience

1 reference

12 December 2020

Effects of uricosuric and antiuricosuric agents on urate transport in human brush-border membrane vesicles.

1 reference

12 December 2020

The implications of noncompliance with antihypertensive medication

1 reference

12 December 2020

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

1 reference

12 December 2020

Angiotensin converting enzyme (ACE) inhibitors and kinin metabolism: evidence that ACE inhibitors may inhibit a kininase other than ACE.

1 reference

12 December 2020

Human AT1 receptor is a single copy gene: characterization in a stable cell line

1 reference

12 December 2020

Hypertension in Diabetes Study IV. Therapeutic requirements to maintain tight blood pressure control

1 reference

12 December 2020

Effect of eprosartan and enalapril in the treatment of elderly hypertensive patients: subgroup analysis of a 26-week, double-blind, multicentre study. Eprosartan Multinational Study Group

1 reference

12 December 2020

Effect of eprosartan and enalapril in the treatment of black hypertensive patients: subgroup analysis of a 26-week, double-blind, multicentre study. Eprosartan Multinational Study Group

1 reference

12 December 2020

Assessment of once-daily eprosartan, an angiotensin II antagonist, in patients with systemic hypertension. Eprosartan Study Group.

1 reference

12 December 2020

Characterization of [3H]SK&F 108566 as a radioligand for angiotensin type-1 receptor

1 reference

12 December 2020

Role of trough to peak efficacy in the evaluation of antihypertensive therapy.

1 reference

12 December 2020

Isolated systolic hypertension in the elderly: lessons from clinical trials and future directions.

1 reference

12 December 2020

Pharmacology of the angiotensin II receptor antagonist, eprosartan

1 reference

12 December 2020

Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study

1 reference

12 December 2020

Angiotensin-converting enzyme inhibitors and cough: a prospective evaluation in hypertension and in congestive heart failure

1 reference

12 December 2020

Pharmacokinetics of intravenously and orally administered eprosartan in healthy males: absolute bioavailability and effect of food.

1 reference

12 December 2020

1 reference

12 December 2020

10.2165/00003495-200060010-00009

Identifiers

DOI

1 reference

Dimensions Publication ID

30 July 2017

1012863601

0 references

Fatcat ID

release_5b5rwrr5znfrhca5xdi62ds53y

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/5b5rwrr5znfrhca5xdi62ds53y

24 November 2022

mapped directly with Wikidata item

1 reference